WATCHMAN

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Boston Scientific warns its August cyberattack could hurt 2026 sales and adjusted profit after a network outage disrupted medical-device manufacturing, order processing and customer shipments. Representative image.

Boston Scientific’s cyberattack knocks its 2026 outlook off course

Manufacturing, order fulfilment and shipping have been restored, but the medical-device group still cannot quantify the full financial damage and will reset expectations with third-quarter results.

byVenkatesh

September 23, 2026

Boston Scientific (BSX) Q2 2026 beats estimates as MiRus TAVR investment reshapes strategy

Boston Scientific lifted FY 2026 guidance and disclosed a $1.5B MiRus TAVR bet, but BSX trades near 52-week lows as softer Q3 growth guidance stings.

byVenkatesh

July 29, 2026

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Boston Scientific’s cyberattack knocks its 2026 outlook off course

Boston Scientific (BSX) Q2 2026 beats estimates as MiRus TAVR investment reshapes strategy

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

SAMILBIO expands Chaeyun skincare with two November launches as K-beauty exports reach $11.1bn

Schneider Electric Infrastructure (SCHNEIDER) shares fall 3.5% despite new factory expansion: What will November results reveal?

Haleon (HLN) near 319p: Does a 15% share-price crash make its valuation attractive after the growth downgrade?

Ethan Allen will split CEO and chair roles, but who gets to choose Farooq Kathwari’s successor?